Recent Generic Launches
Several new generics have launched in the United States, including for the migraine therapy Zomig, the anticancer therapy Doxil, and an anti-inflammatory used to treat respiratory conditions associated with COVID-19.
Padagis Launches Generics of Zomig, Doxil
Padagis has launched a generic version of Zomig (zolmitriptan) Nasal Spray, which is used to treat adults and adolescents with migraine headaches with or without aura. The company has also launched a generic version of the anticancer agent Doxil (doxorubicin liposome injection) through its partnership with Ayana Pharma. Doxil is an anthracycline topoisomerase inhibitor that is used to treat patients with ovarian cancer, AIDS-related Kaposi’s sarcoma and multiple myeloma.
These are the company’s first launches since it separated from Perrigo in July 2021.
Amneal Launches Generic of Decadron
Amneal Pharmaceuticals has launched a generic version of Decadron, an anti-inflammatory glucocorticoid steroid used to treat several medical conditions, including respiratory complications associated with COVID-19.
Additionally the FDA has approved Amneal Pharmaceuticals’ abbreviated new drug application for difluprednate ophthalmic emulsion a generic version of Durezol and is used in the treatment of inflammation and pain associated with ocular surgery.
Endo Launches Generic of Miacalcin for Osteoporosis
Endo International’s Par Sterile Products business has begun shipping calcitonin salmon injection, a generic of Viatris’ Miacalcin, for the treatment of patients with hypercalcemic emergencies. It is also used for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause and to treat symptomatic Paget’s disease of bone.
It is offered in multi-dose vials (2 mL), and is manufactured in a U.S. facility in Rochester, Michigan.
Dr. Reddy’s Launches Generic of Akovaz
Dr. Reddy’s has launched Ephedrine Sulfate Injection 50 mg/mL, a therapeutic equivalent generic version of Exela Pharma’s Akovaz, which treats low blood pressure.
The product, which is a clear, colorless, sterile solution for intravenous injection and supplied as a 1 mL fill in a 2 mL clear glass single-dose vial with purple flip-off cap.
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More
